Masana ilimin cututtukan dabbobi sun kiyasta cewa sama da mutane miliyan 160 a duk duniya sun murmure daga COVID-19

Masana ilimin cututtukan dabbobi sun kiyasta cewa sama da mutane miliyan 160 a duk duniya sun murmure daga COVID-19.Waɗanda suka murmure suna da ƙanƙara mai ƙaranci na maimaita cututtuka, cututtuka ko mutuwa.Wannan rigakafi ga cututtuka na baya yana kare mutane da yawa waɗanda a halin yanzu ba su da maganin rigakafi.
A farkon wannan watan, Hukumar Lafiya ta Duniya ta fitar da wani sabon sabuntawa na kimiyya wanda ke nuna cewa yawancin mutanen da ke murmurewa daga COVID-19 za su sami karfin kariya ta kariya.Mahimmanci, sun yanke shawarar cewa a cikin makonni 4 na kamuwa da cuta, 90% zuwa 99% na mutanen da ke murmurewa daga COVID-19 za su haɓaka ƙwayoyin rigakafin da za a iya gano su.Bugu da ƙari, sun kammala-la'akari da iyakacin lokaci don lura da lokuta-maganin rigakafi ya kasance mai ƙarfi don akalla watanni 6 zuwa 8 bayan kamuwa da cuta.
Wannan sabuntawa ya yi daidai da rahoton NIH a cikin Janairu 2021: Fiye da kashi 95% na mutanen da suka murmure daga COVID-19 suna da martanin rigakafi wanda ke da dindindin na ƙwaƙwalwar ƙwayar cuta har zuwa watanni 8 bayan kamuwa da cuta.Cibiyar Kiwon Lafiya ta Kasa ta kara nuna cewa wadannan binciken sun “ba da bege” cewa mutanen da aka yi wa allurar za su samar da irin wannan rigakafi mai dorewa.
Don haka me yasa muke mai da hankali sosai ga rigakafin rigakafin da aka haifar - a cikin burinmu na cimma rigakafin garken garken, binciken mu kan tafiye-tafiye, ayyukan jama'a ko na sirri, ko amfani da abin rufe fuska - alhali muna yin watsi da rigakafi na halitta?Shin waɗanda ke da rigakafi ba za su iya ci gaba da ayyukan “al’ada” ba?
Masana kimiyya da yawa sun gano cewa hadarin sake kamuwa da cutar ya ragu, kuma asibiti da mace-mace saboda sake kamuwa da cutar ba su da yawa.A cikin bincike shida da ke rufe kusan mutane miliyan 1 da Amurka, Burtaniya, Denmark, Austria, Qatar, da kuma Marine Corps suka gudanar, raguwar sake kamuwa da COVID-19 ya tashi daga 82% zuwa 95%.Binciken na Austriya ya kuma gano cewa yawan sake kamuwa da cutar ta COVID-19 ya haifar da kashi 5 cikin 14,840 kawai (0.03%) aka kwantar da su a asibiti, kuma 1 daga cikin mutane 14,840 (0.01%) ya mutu.
Bugu da kari, sabbin bayanan Amurka da aka fitar bayan sanarwar NIH a watan Janairu sun gano cewa rigakafin rigakafi na iya wuce watanni 10 bayan kamuwa da cuta.
Yayin da masu tsara manufofin kiwon lafiyar jama'a ke rage rigakafi zuwa matsayin rigakafi, tattaunawa sun yi watsi da sarkar tsarin garkuwar jikin dan adam.Akwai rahotannin bincike da yawa masu ƙarfafawa waɗanda ke nuna cewa ƙwayoyin jini a cikin jikinmu, abin da ake kira “kwayoyin B da ƙwayoyin T”, suna ba da gudummawa ga rigakafin salula bayan COVID-19.Idan rigakafin SARS-CoV-2 yayi kama da na sauran cututtukan coronavirus masu tsanani, kamar rigakafin SARS-CoV-1, to wannan kariyar na iya ɗaukar akalla shekaru 17.Koyaya, gwaje-gwajen da ke auna garkuwar salula suna da rikitarwa kuma suna da tsada, wanda ke sa su wahalar samu da hana amfani da su a aikin likita na yau da kullun ko binciken lafiyar jama'a.
FDA ta ba da izinin gwaje-gwajen rigakafi da yawa.Kamar kowane gwaji, suna buƙatar farashi na kuɗi da lokaci don samun sakamako, kuma aikin kowane gwaji yana da bambance-bambance masu mahimmanci a cikin abin da ingantaccen maganin rigakafi ke wakilta.Bambanci mai mahimmanci shine cewa wasu gwaje-gwaje kawai suna gano ƙwayoyin rigakafi da aka samo bayan kamuwa da cuta ta halitta, ƙwayoyin rigakafi na "N", yayin da wasu ba za su iya bambanta tsakanin kwayoyin halitta ko alurar rigakafi ba, "S" antibodies.Likitoci da marasa lafiya yakamata su mai da hankali kan wannan kuma su tambayi waɗanne ƙwayoyin rigakafin gwajin da gaske suke yi.
A makon da ya gabata, a ranar 19 ga Mayu, FDA ta fitar da wata jarida ta kare lafiyar jama'a tana mai bayyana cewa duk da cewa gwajin rigakafin SARS-CoV-2 yana taka muhimmiyar rawa wajen gano mutanen da suka kamu da kwayar cutar ta SARS-CoV-2 kuma suna iya haɓaka rigakafi na daidaitawa. Amsar aiki, gwajin rigakafin mutum bai kamata a yi amfani da shi don tantance rigakafi ko kariya daga COVID-19 ba.Ko?
Ko da yake yana da mahimmanci a kula da saƙon, yana da ruɗani.FDA ba ta ba da wani bayani ba a cikin gargaɗin kuma ta bar waɗanda aka gargaɗe ba su da tabbas dalilin da ya sa ba za a yi amfani da gwajin rigakafi don tantance rigakafi ko kariya daga COVID-19 ba.Sanarwar FDA ta ci gaba da cewa ya kamata wadanda ke da gogewa a gwajin rigakafin su yi amfani da gwajin rigakafin.babu taimako.
Kamar yadda yake da abubuwa da yawa na martanin gwamnatin tarayya ga COVID-19, maganganun FDA sun koma baya a kimiyya.Ganin cewa kashi 90 zuwa 99% na mutanen da ke murmurewa daga COVID-19 za su haɓaka ƙwayoyin rigakafin da za a iya gano su, likitoci na iya amfani da gwajin da ya dace don sanar da mutane haɗarin su.Za mu iya gaya wa marasa lafiya cewa mutanen da suka murmure daga COVID-19 suna da ƙaƙƙarfan rigakafi na kariya, wanda zai iya kare su daga sake kamuwa da cuta, asibiti, da mutuwa.A haƙiƙa, wannan kariyar ta yi kama da ko mafi kyau fiye da rigakafin rigakafin da aka haifar.A taƙaice, mutanen da suka murmure daga kamuwa da cuta a baya ko kuma waɗanda ke da ƙwayoyin rigakafi da za a iya gano su ya kamata a ɗauke su a matsayin kariya, kamar mutanen da aka yi musu allurar.
Neman gaba, masu tsara manufofi yakamata su haɗa da rigakafi na halitta kamar yadda aka ƙaddara ta ingantaccen gwajin rigakafin ƙwayoyin cuta ko takaddun cututtukan da suka gabata (tabbatattun PCR ko gwaje-gwajen antigen) a matsayin hujja iri ɗaya na rigakafi kamar rigakafin.Ya kamata wannan rigakafin ya kasance yana da matsayin zamantakewa iri ɗaya kamar rigakafin rigakafin da aka haifar.Irin wannan manufar za ta rage damuwa sosai da kuma ƙara damar yin balaguro, ayyuka, ziyarar iyali, da dai sauransu. Manufofin da aka sabunta za su ba da damar waɗanda suka murmure su yi murna da dawowar su ta hanyar gaya musu game da rigakafi, ba su damar zubar da abin rufe fuska, nuna fuskokinsu. da shiga rundunar da aka yi wa allurar.
Jeffrey Klausner, MD, MPH, farfesa ne na asibiti na maganin rigakafi a Keck School of Medicine a Jami'ar Kudancin California, Los Angeles, kuma tsohon jami'in likita na Cibiyar Kula da Cututtuka da Cututtuka.Noah Kojima, MD, likita ne a cikin likitancin ciki a Jami'ar California, Los Angeles.
Klausner shine darektan likita na kamfanin gwajin Curative kuma ya bayyana kudaden Danaher, Roche, Cepheid, Abbott da Kimiyya na Phase.A baya ya sami tallafi daga NIH, CDC, da masana'antun gwaji masu zaman kansu da kamfanonin harhada magunguna don bincika sabbin hanyoyin ganowa da magance cututtuka.
Abubuwan da ke wannan gidan yanar gizon don tunani ne kawai kuma ba madadin shawarwarin likita ba, ganewar asali ko jiyya da kwararrun ma'aikatan kiwon lafiya suka bayar.© 2021 MedPage Yau, LLC.duk haƙƙin mallaka.Medpage Yau yana ɗaya daga cikin alamun kasuwanci na tarayya mai rijista na MedPage A Yau, LLC kuma maiyuwa ba za a yi amfani da shi ta wasu kamfanoni ba tare da izini na musamman ba.